AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

In addition, the resulting aptamer–antidote complex could trigger an immune response, which might exacerbate the adverse effect of the aptamer. The authors observed that two anticoagulant ...